ONC-392

· OncoC4, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for ONC-392, covering 2025-05-23 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors [Phase 3]